#Belgium #Gosselies #Endo Tools #EZFuse system #Devon Bream

Endo Tools Therapeutics Announces New CEO

Endo Tools Therapeutics (ETT), known for its cutting-edge endoscopic medical devices, has recently brought on Devon Bream, MPH, FACHE, as its new Chief Executive Officer. This strategic decision highlights the company’s commitment to bolstering its leadership as it gears up for significant growth and innovation in the medical technology sector.

A Leader with Rich Experience

Devon Bream steps into this crucial role with over 25 years of executive experience in the medical technology and endoscopy fields. His impressive resume includes leadership positions at recognized organizations such as Karl Storz Endoscopy, STERIS Corporation, and Olympus Corporation. Bream's robust background spans global commercial leadership, strategic growth initiatives, and a successful track record in mergers and acquisitions. He has also made his mark in healthcare technology innovation, holding several U.S. patents related to medical imaging and workflow improvements.

Bream earned a Master of Public Health Management degree from UCLA and holds the distinction of being a Fellow of the American College of Healthcare Executives (FACHE). His commitment to the healthcare profession is evident in his active mentoring of emerging healthcare leaders and fostering collaboration among professionals in surgical, interventional, and imaging specialties.

Transition and Future Plans

Alongside Bream’s appointment, Alexandre Chau will be shifting to Chief Operating Officer, ensuring continuity and support in the company's operational strategies. Denis Gestin, chairman of ETT's board, expressed gratitude for Chau's leadership, noting that his vision has been vital in steering ETT to this pivotal point of evolution.

Bream echoes these sentiments, stating, "Alexandre’s dedication has laid a strong foundation for commercial growth, and I look forward to collaborating closely with him as we embark on the next phase of our journey."

ETT is on a path of expansion with its recently FDA 510(k) cleared endomina EZFuse system. This advancement opens new doors to enhance procedural efficiency in endoscopic practices, particularly in the United States. The device has received positive feedback from physicians, underscoring its value in streamlining workflows while maintaining patient safety and care quality.

In the near future, Bream plans to actively engage gastrointestinal (GI) clinicians, surgeons, and healthcare facilities across the U.S. to demonstrate the benefits of the EZFuse system firsthand. He affirmed, "We have developed an innovative solution that addresses critical unmet needs in endoscopic procedures. I am thrilled to be working with our talented team, physician partners, and clients as we expand access to minimally invasive solutions, improving patient outcomes globally."

About Endo Tools Therapeutics

Headquartered in Gosselies, Belgium, Endo Tools Therapeutics focuses on creating advanced and minimally invasive endoscopic medical devices. Its mission is clear: to enhance the repertoire of gastrointestinal procedures that can be accomplished using standard gastroscopes, thereby improving patient outcomes and reducing procedural burdens. The endomina platform is currently utilized in Europe and certain Middle Eastern countries for treating obesity through endoscopic gastroplasty, while in the United States, it has been cleared for suturing and soft tissue approximation tasks in the GI tract.

As Endo Tools Therapeutics welcomes Bream to its helm, the medical community watches with anticipation for what innovations and growth will unfold in the expansion of minimally invasive treatment solutions.